Azithromycin With Methylprednisolone (Medrol Dose Pack) Safety
Available evidence does not show a clinically meaningful pharmacokinetic interaction between azithromycin and methylprednisolone. [1]
In a large clinical safety assessment of azithromycin, no pharmacokinetic interactions were observed with methylprednisolone. [2]
Drug-Interaction Evidence
- No pharmacokinetic interaction between azithromycin and methylprednisolone has been observed in clinical data. [2]
- Ex-vivo ECMO circuit testing showed stable azithromycin and methylprednisolone concentrations over 6 hours, with no statistically significant difference in recovery versus controls. [1]
Practical Safety Considerations
- Monitoring for known adverse effects of each medication is recommended, since absence of a specific drug-drug pharmacokinetic interaction does not eliminate the possibility of overlapping side effects. [2]
- Medication lists should be reviewed for other interacting drugs (especially other causes of QT prolongation or other interacting agents), since azithromycin’s clinically relevant interaction burden is driven more by comedications than by methylprednisolone. [2]
When Extra Caution or Clinical Reassessment Is Needed
- Clinical reassessment is recommended for patients with significant cardiac disease or those taking other QT-prolonging drugs, because azithromycin safety can be affected by comedications and patient-specific risk factors. [2]
- Clinical reassessment is recommended for patients with diabetes or history of steroid-induced hyperglycemia, since methylprednisolone can worsen glycemic control. [2]
Key Counseling Points for a Medrol Dose Pack + Azithromycin
- Coadministration can be used without expecting a methylprednisolone–azithromycin pharmacokinetic interaction. [1]
- Adverse effects should be monitored, with prompt contact with the prescribing clinician for concerning symptoms (for example, severe palpitations, syncope, or severe allergic-type reactions). [2]